Skip Nav Destination
Issues
15 September 2006
-
Cover Image
Cover Image
Antitumor immune response changes drastically during the development and progression of cancers. We demonstrated that the prevalence of FOXP3+ regulatory T cells is increased in pancreatic ductal adenocarcinoma and is an independent prognostic factor. Furthermore, infiltration of FOXP3+ regulatory T cells is closely correlated to the progression of premalignant lesions of pancreatic cancer, suggesting that FOXP3+ regulatory T cells play a role in controlling the immune response in pancreatic multistep carcinogenesis. The photograph shows newly established monoclonal antibody detecting FOXP3 (green) in CD4+CD25+ regulatory T cells and few CD8+ T cells (red) of lymph node in formalin-fixed paraffin-embedded section. For further details, please see Hiraoka et al. on page 5423 in this issue. - PDF Icon PDF LinkTable of Contents
ISSN 1078-0432
EISSN 1557-3265
Editor’s Note
Editorial
The Biology Behind
Molecular Pathways
CCR Focus
Report from the FDA
Approval Summary: Nelarabine for the Treatment of T-Cell Lymphoblastic Leukemia/Lymphoma
Martin H. Cohen; John R. Johnson; Tristan Massie; Rajeshwari Sridhara; W. David McGuinn, Jr.; Sophia Abraham; Brian P. Booth; M. Anwar Goheer; David Morse; Xiao H. Chen; Nallaperumal Chidambaram; Leslie Kenna; Jogarao V. Gobburu; Robert Justice; Richard Pazdur
Review
Human Cancer Biology
Imaging, Diagnosis, Prognosis
Cancer Therapy: Clinical
In vitro Drug Sensitivity Predicts Response and Survival after Individualized Sensitivity-Directed Chemotherapy in Metastatic Melanoma: A Multicenter Phase II Trial of the Dermatologic Cooperative Oncology Group
Selma Ugurel; Dirk Schadendorf; Claudia Pföhler; Karsten Neuber; Adina Thoelke; Jens Ulrich; Axel Hauschild; Konstanze Spieth; Martin Kaatz; Werner Rittgen; Stefan Delorme; Wolfgang Tilgen; Uwe Reinhold
A Phase I Biological and Pharmacologic Study of the Heparanase Inhibitor PI-88 in Patients with Advanced Solid Tumors
Michele Basche; Daniel L. Gustafson; Scott N. Holden; Cindy L. O'Bryant; Lia Gore; Samir Witta; Mary Kay Schultz; Mark Morrow; Adrah Levin; Brian R. Creese; Michael Kangas; Kaye Roberts; Thu Nguyen; Kat Davis; Russell S. Addison; Jane C. Moore; S. Gail Eckhardt
Pharmacogenetics of Capecitabine in Advanced Breast Cancer Patients
Rémy Largillier; Marie-Christine Etienne-Grimaldi; Jean-Louis Formento; Joseph Ciccolini; Jean-François Nebbia; Aurélie Ginot; Mireille Francoual; Nicole Renée; Jean-Marc Ferrero; Cyril Foa; Moïse Namer; Bruno Lacarelle; Gérard Milano
Phase I Study of Abagovomab in Patients with Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Paul Sabbatini; Jakob Dupont; Carol Aghajanian; Felicia Derosa; Elizabeth Poynor; Sybil Anderson; Martee Hensley; Phillip Livingston; Alexia Iasonos; David Spriggs; William McGuire; Silke Reinartz; Sally Schneider; Cathy Grande; Shashikant Lele; Kerry Rodabaugh; James Kepner; Soldano Ferrone; Kunle Odunsi
Cancer Therapy: Preclinical
Human Regulatory T Cells Control Xenogeneic Graft-versus-Host Disease Induced by Autologous T Cells in RAG2−/−γc−/− Immunodeficient Mice
Tuna Mutis; Rozemarijn S. van Rijn; Elles R. Simonetti; Tineke Aarts-Riemens; Maarten E. Emmelot; Louis van Bloois; Anton Martens; Leo F. Verdonck; Saskia B. Ebeling
The Thalidomide Analogue, CC-4047, Induces Apoptosis Signaling and Growth Arrest in Childhood Acute Lymphoblastic Leukemia Cells In vitro and In vivo
Shabnam Shalapour; Andrea Zelmer; Madlen Pfau; Eva Moderegger; Cristiane Costa-Blechschmidt; Frank K.H. van Landeghem; Tillmann Taube; Iduna Fichtner; Christoph Bührer; Günter Henze; Karl Seeger; Sven Wellmann
Interleukin 6, a Nuclear Factor-κB Target, Predicts Resistance to Docetaxel in Hormone-Independent Prostate Cancer and Nuclear Factor-κB Inhibition by PS-1145 Enhances Docetaxel Antitumor Activity
Josep Domingo-Domenech; Cristina Oliva; Ana Rovira; Jordi Codony-Servat; Marta Bosch; Xavier Filella; Clara Montagut; Marian Tapia; Clara Campás; Lenny Dang; Mark Rolfe; Jeffrey S. Ross; Pere Gascon; Joan Albanell; Begoña Mellado
Bispecific Antibody Pretargeting of Tumor Neovasculature for Improved Systemic Radiotherapy of Solid Tumors
Dieter Moosmayer; Dietmar Berndorff; Chien-Hsing Chang; Robert M. Sharkey; Axel Rother; Sandra Borkowski; Edmund A. Rossi; William J. McBride; Thomas M. Cardillo; David M. Goldenberg; Ludger M. Dinkelborg
Cancer Susceptibility and Prevention
Letters to the Editor
Advertisement
Email alerts
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.